Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology will host a conference call on November 4 at 4:30 p.m. ET to discuss its financial results for the third quarter of 2026. The call aims to provide a corporate update and will be accessible via the company's website. This event highlights the company's ongoing communication with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vir Biotechnology is hosting a conference call.
  • The call will provide a corporate update.
  • Financial results for Q3 2026 will be discussed.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focus

Frequently Asked Questions

When is the Vir Biotechnology conference call?

The conference call is on November 4 at 4:30 p.m. ET.

What will be discussed during the call?

The call will cover the financial results for Q3 2026.

How can I access the conference call?

The call can be accessed on the Vir Biotechnology website.

What time is the call in PT?

The call is at 1:30 p.m. PT.

ShareAdd on Google
Tags: VIR Vir Biotechnology Q3 2026 financial results conference call corporate update
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$529M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →